Novartis erzielt im ersten Quartal[1] Umsatzsteigerungen (kWk), deutlich höhere Margen (kWk) und beachtliche Innovationen - jetzt mit einem stärker fokussierten Portfolio
April 23, 2015 01:00 ET
|
Novartis Pharma AG
Die fortzuführenden Geschäftsbereiche[1] steigern im ersten Quartal den Umsatz, das operative Kernergebnis[2] und den Kerngewinn pro Aktie (kWk[2]) Der Nettoumsatz beläuft sich auf USD 11,9...
Novartis a affiché, au T1[1], une forte progression de ses ventes (tcc), une hausse importante de sa marge (tcc) et une innovation très dynamique; avec un portefeuille désormais mieux ciblé
April 23, 2015 01:00 ET
|
Novartis Pharma AG
Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat opérationnel...
Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients
April 21, 2015 01:15 ET
|
Novartis Pharma AG
New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four key...
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
April 16, 2015 12:26 ET
|
Novartis Pharma AG
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of...
Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States
April 16, 2015 01:15 ET
|
Novartis Pharma AG
US Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the correction of...
Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients
April 15, 2015 01:15 ET
|
Novartis Pharma AG
Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia...
Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians
April 13, 2015 01:15 ET
|
Novartis Pharma AG
New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding...
Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload
March 30, 2015 17:43 ET
|
Novartis Pharma AG
Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment...
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
March 30, 2015 01:15 ET
|
Novartis Pharma AG
Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances the...
Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients
March 21, 2015 07:00 ET
|
Novartis Pharma AG
After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who were...